Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia

Hospital de Clinicas de Porto Alegre

Status and phase: Unknown; Phase 3

Conditions: Schizophrenia

Treatments: Drug: Amantadine; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00999505

09-303

Details and patient eligibility

About

Amantadine as add-on therapy to antipsychotics may improve schizophrenia positive, negative and cognitive symptoms.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Under antipsychotics with residual symptoms

Exclusion criteria

• Pregnancy
• Lactation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

40 participants in 2 patient groups, including a placebo group

Amantadine

Active Comparator group

Description:

Amantadine 200mg twice a day

Treatment:

Drug: Amantadine

Placebo

Placebo Comparator group

Description:

Placebo capsules twice a day

Treatment:

Drug: Placebo